Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TACROLIMUS

All products: Limited Use (codes 590)

Other products in the same Health Canada class (L04A) — coverage varies; not interchangeable

  • Baricitinib (Olumiant): limited Use 615, 734, Limited Use 734
  • Cladribine (Mavenclad): not a benefit

Envarsus PA · DIN 02485877 · 0.75mg · extended release tablet

Limited Use — Reason for Use code 590 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 590 required
Write on scriptLU code 590 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 590
Reason for Use code 590 For the prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients in combination with other immunosuppressants. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Envarsus PA · DIN 02485877 Manufacturer: Endo Ventures Ltd.; listing date 2020-09-30 Health Canada: Marketed since 2026-03-23 · brand ENVARSUS PA · ATC L04AD02 TACROLIMUS · form Tablet (extended-release) · route Oral · ingredients TACROLIMUS 0.75 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Envarsus PA: Formulary list price $2.0999/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0999 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97609 · Verify on the e-Formulary ↗ (DIN 02485877)

Source record
DIN 02485877: Envarsus PA Raw flags: sec12=Y, sec3=Y Item: 924400008; group id 1046; item number 2398; lccId 00340; manufacturer id EVL Source form: ER Tab; strength: 0.75mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0999; ministry $2.0999 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485877 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97609
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (92:44 Immunosuppressive Agents) and how they are covered

Matched class: 92:44 Immunosuppressive Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 92:44 Immunosuppressive Agents

BARICITINIB

· 2 products · Limited Use, codes 615, 734 (1), Limited Use, codes 734 (1) · strengths: 2mg, 4mg · Tab

CLADRIBINE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:44
Full class listing Related classes: 92:20 Biologic Response Modifiers, 92:36 Disease-Modifying Antirheumatic Agents, 92:92 Other Miscellaneous Therapeutic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: active rheumatoid arthritis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: LEFLUNOMIDE, PENICILLAMINE, SULFASALAZINE CYCLOSPORINE · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (8) Rheumatoid Arthritis NEORAL capsules and oral solution (cyclosporine) are also indicated for the treatment of severe active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents are inappropriate or ineffective. PM: https://pdf.hres.ca/dpd_pm/00085584.PDF; date 2026-07-30; DIN 02150662; fetched 2026-09-10 Product monograph LEFLUNOMIDE · General benefit ARAVA is indicated in adults for the treatment of active rheumatoid arthritis. 1.1 Pediatrics The use in patients less than 18 years of age is contraindicated. 1.2 Geriatrics No dosage adjustment is needed in patients over 65 years of age. PM: https://pdf.hres.ca/dpd_pm/00083555.PDF; date not captured; DIN 02241888; fetched 2026-09-10 Product monograph PENICILLAMINE · General benefit INDICATIONS AND CLINICAL USE CUPRIMINE (penicillamine capsules, USP) is indicated for:  treatment of Wilson's disease  chronic lead poisoning  cystinuria, and  In patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. PM: https://pdf.hres.ca/dpd_pm/00054287.PDF; date not captured; DIN 00016055; fetched 2026-09-10 Product monograph SULFASALAZINE · General benefit It is especially useful for chronic administration. pms-SULFASALAZINE-E.C. is also indicated for the treatment of active rheumatoid arthritis, when treatment with an adequate conventional first line therapy has failed. PM: https://pdf.hres.ca/dpd_pm/00056638.PDF; date April 30, 2020; DIN 00598461; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Transplantation Prograf® (tacrolimus) is indicated for: • prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants. • treatment of refractory rejection in patients receiving allogeneic liver or kidney transplants. Prograf is to be used concomitantly with adrenal corticosteroids and other immunosuppressive agents. The safety and efficacy of the use of Prograf with sirolimus has not been established. Only physicians experienced in immunosuppressive therapy and management of organ transplant should prescribe Prograf (tacrolimus). Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. Rheumatoid Arthritis Prograf (tacrolimus immediate-release capsules, USP) is indicated for: • treatment of active rheumatoid arthritis in adult patients for whom disease modifying anti-rheumatic drug (DMARD) therapy is ineffective or inappropriate. Prograf may be used as monotherapy or in combination with non-st… https://pdf.hres.ca/dpd_pm/00082912.PDF PM date: 2025-12-17 Source product: PROGRAF; DIN 02175983; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.